Two new appointments to BioAlliance Pharma's Supervisory Board
BioAlliance Pharma SA announced the appointment of two new Board members.
The Supervisory Board has co-opted André Ulmann MD, PhD (founder and CEO of HRA Pharma since 1996) and the company ING Belgium (represented by Denis Biju-Duval, BEng, MBA, Head of ING Belgium's private equity team since 2001) following the departure of Georges Hibon and Philippe Taranto.
New Board member André Ulmann will contribute his entrepreneurial experience within HRA, a fast-growing European company which develops and commercializes drugs in the reproductive health and endocrinology markets. Furthermore, the core BioAlliance Pharma shareholder ING Belgium has confirmed its midterm commitment to the company.
Furthermore, AGF Private Equity (another core shareholder and a current Board member) has appointed Rémi Droller (Partner, managing investments in Healthcare) as its permanent representative. Rémi Droller holds an M.Phil. in Molecular Biology and a Masters in Innovation Management.
Other news from the department people
